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ABSTRACT
DNA interstrand crosslinks (ICLs) formed by
antitumor agents, such as cisplatin or mitomycin
C, are highly cytotoxic DNA lesions. Their repair is
believed to be triggered primarily by the stalling of
replication forks at ICLs in S-phase. There is,
however, increasing evidence that ICL repair can
also occur independently of replication. Using a
reporter assay, we describe a pathway for the
repair of cisplatin ICLs that depends on transcrip-
tion-coupled nucleotide excision repair protein CSB,
the general nucleotide excision repair factors XPA,
XPF and XPG, but not the global genome nucleotide
excision repair factor XPC. In this pathway, Rev1
and Polf are involved in the error-free bypass of cis-
platin ICLs. The requirement for CSB, Rev1 or Polf is
specific for the repair of ICLs, as the repair of
cisplatin intrastrand crosslinks does not require
these genes under identical conditions. We directly
show that this pathway contributes to the removal
of ICLs outside of S-phase. Finally, our studies
reveal that defects in replication- and transcrip-
tion-dependent pathways are additive in terms of
cellular sensitivity to treatment with cisplatin or
mitomycin C. We conclude that transcription- and
replication-dependent pathways contribute to cellu-
lar survival following treatment with crosslinking
agents.
INTRODUCTION
DNA interstrand crosslinks (ICLs) are formed by widely
used chemotherapeutic agents [cisplatin, mitomycin C
(MMC), nitrogen mustards, nitrosoureas], as well as by
endogenous products of lipid peroxidation (1–3).
Because ICLs block essential aspects of DNA metabolism,
such as replication and transcription, they are highly cyto-
toxic. The repair of ICLs is of substantial relevance
because the efﬁciency of crosslink repair is a determinant
of how tumor cells respond to chemotherapy with ICL-
inducing agents (4–6). In vertebrates, ICL repair is pri-
marily triggered by stalled replication forks during
S-phase. This pathway requires endonucleases (ERCC1-
XPF, MUS81-EME1, FAN1), translesion synthesis poly-
merases (Polz, Rev1), Fanconi anemia (FA) proteins and
homologous recombination factors (7,8).
However, there is increasing evidence for the existence
of a second ICL repair pathway that is independent of
replication and recombination, and that occurs primarily
in the G0/1 phase of the cell cycle (9,10). Replication-
independent ICL repair was originally described in
bacteria (11,12). A similar pathway is conserved from
yeast to mammals and is believed to involve nucleotide
excision repair (NER) factors to recognize and incise
ICLs, and the translesion polymerases Rev1 and Polz to
bypass an unhooked ICL intermediate (13–17). Because
the cells deﬁcient in NER factors (other than
ERCC1-XPF) are only mildly sensitive to ICL-generating
agents, it has been suggested that the replication-
independent pathway plays a relatively minor role in ver-
tebrates. However, it is also possible that the importance
of the G1 pathway in removing ICLs is underappreciated
because ICLs are more readily tolerated in G1 than in the
S-phase, where stalling of a replication fork is highly toxic.
In contrast, ICL toxicity in G1 may only be manifest if it
blocks the transcription of an essential gene.
We set out to characterize the replication-independent
repair of ICLs and to study its relation to transcription
and to the NER-dependent repair of single-stranded
*To whom correspondence should be addressed. Tel: +1 631 632 7545; Fax: +1 631 632 7546; Email: orlando@pharm.stonybrook.edu
Published online 18 July 2012 Nucleic Acids Research, 2012, Vol. 40, No. 18 8953–8964
doi:10.1093/nar/gks670
 The Author(s) 2012. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
lesions, such as intrastrand crosslinks generated by the
same agents. We decided to study DNA adducts generated
by cisplatin because it is the clinically most important
crosslinking agent and because the relative distribution
of 1,2-d(GpG), 1,2-d(ApG) and 1,3-d(GpNpG)
intrastrand crosslinks, and 1,2-d(GpC) ICLs, generated
by this compound (65%, 25%, 5–10% and 2–5% of
total adducts, respectively) is known (18). The recognition
and repair of cisplatin intrastrand and ICLs by NER has
been investigated by biochemical approaches, and it was
found that only intrastrand crosslinks are repaired by
NER in cell extracts (19,20). The repair of site-speciﬁc
intrastrand cisplatin adducts in mammalian cells has, fur-
thermore, been studied in a plasmid-based reporter system
in mammalian cells (21). To address the mechanism of
repair of the three different cisplatin adducts, 1,2-GpC
interstrand, and 1,3-GTG and 1,2-GG intrastrand
crosslinks, we developed a reporter assay that reﬂects con-
ditions of repair in the G1 phase of the cell cycle. We
found that under our experimental conditions the repair
of cisplatin ICLs, but not intrastrand crosslinks, is de-
pendent on a transcription-coupled NER (TC-NER)
pathway and the translesion synthesis polymerases Polz
and Rev1. We show that inhibition of replication-
dependent ICL repair further sensitizes the cells with a
defect in TC-NER, suggesting that cisplatin ICLs are
repaired in the G1 and S-phases of the cell cycle.
MATERIALS AND METHODS
Generation of oligonucleotides containing a cisplatin
interstrand or intrastrand crosslink at deﬁned positions
A short DNA duplex containing a single cisplatin ICL was
prepared using the procedure described by Hofr and
Brabec (22). Brieﬂy, a 50-phosphorylated oligonucleotide
containing a unique G (Figure 1B, upper strand) was
synthesized, puriﬁed by polyacrylamide gel electrophoresis
(PAGE) and used to generate the cisplatin monoadduct by
reacting with cisplatin activated to a monoaquamono-
chloro derivative, and puriﬁed on a MonoQ column.
The puriﬁed monoadduct was annealed with the
50-phosphorylated complementary strand and allowed to
form the crosslink. The ICL product was puriﬁed on a
MonoQ column under denaturing conditions.
For the synthesis of the intrastrand adducts, oligo-
nucleotides containing either a unique GTG (Figure 1C)
or a GG (Figure 1D) site for platination were allowed to
react with activated cisplatin to produce the 1,3- and the
1,2-intrastrand crosslinks, respectively, following pub-
lished protocols (23). After puriﬁcation, the site-speciﬁcally
modiﬁed oligonucleotides were allowed to anneal to their
complementary strands. All DNA duplexes contained two
different 4-nucleotide overhangs (Figure 1B–D) to allow
incorporation into a plasmid.
Preparation of site-speciﬁcally modiﬁed
reporter substrates
The luciferase reporter plasmid was derived from the
backbone of pCX-NNX-EGFP plasmid (24) (gift of
Bevin Engelward, MIT) by replacing the EGFP gene
with the Renilla luciferase gene from the plasmid
phRG-B (Promega). A tandem BbsI restriction site was
cloned upstream of the coding region of the reporter
gene to yield the pCX-RLuc plasmid (Figure 1A), into
which the various crosslink-containing duplexes were
ligated. Digest of pCX-RLuc with BbsI yielded two differ-
ent nonpalindromic 4-nucleotide 50 cohesive ends comple-
mentary to those of the crosslinked duplexes. The
linearized pCX-RLuc was separated from the short
fragment on a gel ﬁltration column and used to ligate
the lesion-containing inserts or the undamaged oligo-
nucleotides. The closed circular form of the plasmid was
puriﬁed by CsCl-ethidium bromide gradient ultracentrifu-
gation. A detailed protocol for the preparation of
ICL-containing plasmids was published in (25).
Cell lines and tissue culture conditions
Simian virus 40 (SV40)-transformed human ﬁbroblasts
GM00637 (wild type), GM08437 (XP-F), GM04312
(XP-A), GM 15876 (GM04312 complemented with the
full length cDNA of XPA), GM 15983 (XP-C) and GM
16248 (GM 15983 stably transfected with XPC-cDNA)
from Coriell Cell repositories, and XPCS1RO (XP-G)
from Stuart Clarkson (Centre Me´dical Universitaire,
Geneva, Switzerland) (26) were grown in Dulbecco’s
Modiﬁed Eagles Medium (DMEM) supplemented with
10% fetal bovine serum (FBS). The mouse embryonic
ﬁbroblasts (MEFs), wild type and mutants Rev3/ (27),
Rev1/ (28), Msh2/ (RH95021) and Msh2+/+
(RH95673) (29) established by Niels de Wind (Leiden
University Medical Center, the Netherlands) were grown
in DMEM supplemented with 10% fetal calf serum (FCS).
The Cockayne syndrome B (CS-B) ﬁbroblasts CS1AN-SV
and CS1AN-SV dtCSB (stably expressing functional and
physiological levels of HA-/His6 double-tagged CSB) from
Wim Vermeulen (Erasmus Medical Center, Rotterdam,
the Netherlands) (30), the Chinese hamster cells AA8
(ovary, wild type), V79B (wild-type lung ﬁbroblasts)
UV41 (XPF), UV5 (XPD), irs1SF (XRCC3) and irs1
(XRCC2) mutants derived from them (kindly provided
by Roland Kanaar, Erasmus Medical Center, Rotterdam,
the Netherlands), were maintained in DMEM/Nutrient
Mixture Ham’s F-10 (1:1) and 10% FBS. The 293T La
cell line was propagated as described (31). The Pol/
(M6) and Pol+/+ (M1) MEFs (32) (a kind gift from
Tomoo Ogi and Haruo Ohmori, Institute for Virus
Research, Kyoto University, Japan) and the Pol-deﬁcient
(240-1) and Pol-proﬁcient (238-0) MEFs (33) (from Alan
Lehmann, Genome Damage and Stability Center,
University of Sussex, UK) were grown in DMEM supple-
mented with 15% FCS. The isogenic pair of xeroderma
pigmentosum variant (XP-V) human ﬁbroblasts
(GM02359-hTERT) and complemented with the Pol
cDNA (GM02359-hTERT+XPV), kindly provided by
Marila Cordeiro-Stone (University of North Carolina at
Chapel Hill) (34), were maintained in DMEM supple-
mented with 2 the concentration of MEM nonessential
amino acids, 10% FCS and 200 mg/ml G418. The
XP30RO (XP-V) ﬁbroblasts and the corrected cells
(XP30RO+ Pol cDNA) from Alan Lehmann (35) were
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grown in DMEM supplemented with 10% FBS. Two
isogenic pairs of SV40-transformed FA ﬁbroblasts,
PD20.F (FA-D2) and corrected (PD20.F+FANCD2),
GM6914 (FA-A) and corrected (GM6914+FANCA)
(36), kindly provided by Alan D’Andrea, and the
EUFA030 (FA-J) and corrected (EUFA0030+FANCJ)
(kindly provided by J. de Winter) (37), were grown in
DMEM supplemented with 15% FBS. All cell lines were
cultured at 37C in a CO2 humidiﬁed atmosphere.
Reporter reactivation assay
For transfection experiments, cells were plated on 24-well
plates in antibiotic-free media and allowed to grow for
24 h to achieve 40–60% conﬂuency at the time of trans-
fection. To minimize the experimental variability caused
by differences in cell viability or transfection efﬁciency, the
Dual-Luciferase Reporter Assay System (Promega) was
used. The unmodiﬁed or site-speciﬁcally crosslinked
Renilla luciferase experimental reporter plasmid were
co-transfected with the pGL3-Control Vector (Promega)
that contains the ﬁreﬂy luciferase gene and serves as an
internal control to normalize the activity of the experimen-
tal reporter. Transfections were performed using 10 ng of
the reporter and 0.5 ng of the control plasmids (20:1 ratio)
and the Lipofectamine Plus Reagent (Invitrogen) (0.6 ml
Lipofectamine and 0.9ml Plus Reagent) for 6 h in
serum-free media. For cells that were difﬁcult to transfect,
100 ng carrier DNA was added to improve the transfec-
tion efﬁciency. After removing the transfection media,
cells were incubated in complete media for 20 h, then
lysed in 100 ml passive lysis buffer provided with the
Dual Luciferase Reporter Assay kit (Promega). The
lysates were stored at 80C until they were assayed.
The assays for ﬁreﬂy and Renilla luciferase activities
were performed sequentially within the same sample, ac-
cording to the procedure recommended by the supplier,
using a Labsystems Luminoskan.
Mutation analysis
To analyse the accuracy of the repair at the site of the
crosslink, 40 ng of the site-speciﬁcally modiﬁed plasmid
was transfected into cells in 24-well plates, and 20 h after
transfection, the DNA was isolated using the QIAprep
Spin Miniprep Kit (Qiagen). The DNA was electro-
porated into the NER- and recombination-deﬁcient
Escherichia coli strain AB2480 (uvrA6recA13) (38), and
the isolated ampicillin-resistant clones were analysed by
BsrBI digest. Clones that were resistant to BsrBI digest
at the site of the crosslink were further analysed by
DNA sequencing.
RNA interference
The day before transfection, CS1AN-SV and CS1AN-SV
dtCSB cells were seeded at a density of 105 per well in six-
well plates in DMEM/Nutrient Mixture Ham’s F-10 (1:1)
and 10% FBS without antibiotics. Cells at 30–40%
conﬂuency were transfected with 50 pmol siRNA using
Lipofectamine RNAiMAX (Invitrogen) according to the
procedure of the supplier. The siRNA target sequences
were as follows: siLuciferase (CGU ACG CGG AAU
ACU UCG A), siFANCD2 (CAG AGU UUG CUU
CAC UCU CUA). Cell pellets were collected 48 h after
transfection to check the efﬁciency of siRNA-mediated
downregulation. The following primary antibodies were
used for Western blots: FANCD2 (Fl17, Santa Cruz),
CSB (H-300, Santa Cruz), TFIIH p89 (S-19, Santa Cruz).
Cell survival assays
The human ﬁbroblasts were seeded in triplicates in six-well
plates at a density of 500 cells per well. Following incuba-
tion for 8 h, cells were treated with the indicated concen-
trations of cisplatin or MMC, and the media was changed
after 24 h. For experiments with siRNA-mediated down
regulation, cells were plated 24 h after transfection and
treated with the drug 16 h later. After 9–16 days, the
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Figure 1. Construction of the plasmid containing site-speciﬁc cisplatin crosslinks. (A) pCX-RLuc plasmid with two BbsI sites cloned between the
splice acceptor and the Renilla luciferase (hRluc) reporter gene. (B) The sequence of the cisplatin ICL oligonucleotide with the crosslinked guanine
bases shown in bold. The ICL is located within a BsrBI restriction site. (C) The sequence of 1,3-GTG cisplatin intrastrand crosslink located within an
ApaLI restriction site. The modiﬁed bases are shown in bold. (D) The sequence of 1,2-GG cisplatin intrastrand crosslink (modiﬁed bases in
bold). (E) Analysis of the cisplatin ICL containing substrate. A 40-bp fragment was released from the plasmid by SacI digestion and labelled
with a-[32P]-dCTP. The fragments released from the cisplatin ICL (lane 1) or unmodiﬁed control plasmid (lane 2) were analysed by 12% denaturing
PAGE. (F) Restriction analysis of the 1,3-GTG-cisplatin intrastrand crosslink substrate. ApaLI digest releases 3 fragments from unmodiﬁed control
plasmid (1246, 2000 and 2055 bp, the last two are not separated in agarose gel) (lane 2). In the plasmid with the 1,3-GTG cisplatin intrastrand
crosslink, the ApaLI site located at the position of the lesion is completely blocked (ApaLI digest yields fragments of 1246 and 4055 bp) (lane 1). Lane
3: 1 kb DNA Ladder (NEB).
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colonies were ﬁxed and stained with 0.5% crystal violet in
20% ethanol, and individual colonies with more than 30
cells were counted. The number of colonies obtained with
untreated cells was set as 100% survival. Each survival
experiment was performed at least three times.
RESULTS
Construction of plasmids containing site-speciﬁc
cisplatin crosslinks
The strategy to prepare site-speciﬁcally modiﬁed plasmids
is based on a tandem BbsI restriction site, which was
cloned between the splice acceptor and the coding region
of the Renilla luciferase reporter gene, yielding the pCX-
RLuc plasmid (Figure 1A). The two different nonpalin-
dromic 50 overhangs formed after BbsI digestion allow for
the ligation of either unmodiﬁed or lesion-containing
oligonucleotides with complimentary cohesive ends
(Figure 1B–D). This design ensures the incorporation of
a single insert into the plasmid in a controlled orientation.
In the case of 1,2-GG and 1,3-GTG cisplatin intrastrand
crosslinks, the orientation of the BbsI sites was adapted to
speciﬁcally incorporate the lesion into the transcribed
strand. After optimization of the ligation procedure, to
decrease the formation of multimeric species, the
puriﬁed closed circular form was obtained with a repro-
ducible yield of 20–50%. The analysis of the substrates by
denaturing PAGE (a 40 bp fragment containing the ICL)
(Figure 1E) or restriction analysis (inactivation of the re-
striction site ApaLI by the 1,3-GTG cisplatin intrastrand
adduct) (Figure 1F) conﬁrmed the presence of the lesion in
the modiﬁed plasmids. The very low amount of
uncrosslinked material detected with the cisplatin ICL
substrate (<2%) is probably generated during the
sample analysis, as it is known that the stability of
cisplatin ICL is affected in short DNA fragments (39).
However, the cisplatin ICL incorporated into a plasmid
has a good stability and the activity of different restriction
enzymes (BsrBI, SapI, EarI) whose recognition and/or
cutting site overlap with the ICL were completely
blocked (data not shown). The amount of uncrosslinked
material contaminating the crosslinked substrate plasmid
is estimated to be 1.1%, as determined by quantitative
PCR, with a pair of primers ﬂanking the ICL site (data
not shown).
Reactivation of transcription in cisplatin ICL containing
plasmids depends on NER
The reporter plasmid contains the cisplatin ICL in an
actively transcribed region, blocking expression of the
reporter gene; therefore, the ICL needs to be removed to
restore transcription. To quantitatively estimate the
cisplatin ICL repair (measured as the level of reporter
gene expression), the cisplatin ICL plasmid (Renilla
luciferase) was cotransfected into mammalian cells with
an internal control reporter (ﬁreﬂy luciferase). After nor-
malization of the Renilla luciferase activity to that of the
internal control, the relative repair was estimated as the
percentage of the activity obtained with an identical
reporter plasmid that did not contain a lesion (set to
100%). Previous studies using a similar reporter plasmid
with psoralen, MMC or alkyl ICLs showed a dependence
of the repair of the ICL on the NER genes (13,16,17). We
therefore tested the level of reactivation of reporter gene
expression of the ICL-containing plasmid in wild type or
NER-deﬁcient human ﬁbroblast cell lines. The level of
repair was 60% in the wild-type cells (compared with
the non-damaged control), and was decreased to 20%
in ﬁbroblasts from xeroderma pigmentosum patients with
mutations in the XPA, XPF and XPG genes, demonstrat-
ing that the removal of the crosslink was dependent on
functional NER (Figure 2A). Reporter gene expression
was restored to the level of the wild-type cells in an
XP-A cell line complemented with the wild-type XPA,
conﬁrming that the reduced repair of the cisplatin ICL
was indeed due to a defect in NER and not an indirect
effect. Similar levels of ICL repair were found in Chinese
hamster ovary (CHO) cell lines with mutations in the
XPF (UV41) or XPD (UV5) genes (Supplementary
Figure S1A).
We then addressed how the NER-dependent repair of
ICLs compared with that of intrastrand crosslinks in our
reporter assay. Previous biochemical studies revealed that
the 1,3-GTG intrastrand adduct is more efﬁciently
repaired by NER than the 1,2-GG intrastrand adduct,
as the structural alteration induced in the DNA by the
former triggers NER more efﬁciently (19,20,40). We
investigated the reactivation of the Renilla luciferase
reporter gene in plasmids containing the 1,3-GTG or
1,2-GG cisplatin intrastrand adducts on the transcribed
strand, similar to previous studies (21). The repair of the
1,3-GTG adduct showed dependence on the NER factors
XPA and XPG, similar to cisplatin ICLs, and repair was
restored to near wild-type level in the XP-A comple-
mented cells (Figure 2B). In the XP-F cells, the
1,3-GTG adduct was repaired close to wild-type levels,
possibly due to the signiﬁcant residual NER activity
present in these cells (10% of normal post UV unsched-
uled DNA synthesis (41)), which appears to be sufﬁcient
for the removal of the 1,3-GTG intrastrand, but not the
ICL. However, the XPF-mutant CHO cell line UV41
showed a similar level of deﬁciency as the human XPA
and XPG and the CHO UV5 cell lines (Supplementary
Figure S1B), demonstrating the involvement of XPF in
the repair of 1,3-GTG intrastrand adducts. In contrast,
expression of the reporter gene blocked by an 1,2-GG
cisplatin intrastrand adduct is fully reactivated
(80–100%) in either wild-type or NER-mutant cells
(Figure 2C). It is possible that this reﬂects bypass of
1,2-GG cisplatin ICLs by RNA polymerase II as
observed previously in cell extracts under certain condi-
tions (42). We note that the absence of XPF had a slightly
greater impact on repair rates of 1,2-GG and 1,3-GTG
adducts in a previous study (21). However, the impact of
XPF deﬁciency on 1,3-GTG repair was less than of the
absence of XPA or XPG described here. The reason for
these differences is not clear. We note that signiﬁcant
residual reporter gene reactivation is found in the
absence of NER, which may be due to repair and toler-
ance pathways, such as mismatch repair (MMR) and
translesion synthesis (5,6).
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We decided to focus on the 1,3-GTG intrastrand cross-
link to distinguish the requirements for the repair of intra-
and ICLs in our studies. In the conditions used in our
assays, the repair of the 1,3-intrastrand and interstrand
cisplatin adducts was thus achieved by an NER-dependent
mechanism, although there was a more stringent require-
ment for a functional XPF for the repair of the interstrand
adduct.
The repair of cisplatin ICLs is coupled
to transcription
There are two branches of NER: global genome NER
(GG-NER), which can detect bulky DNA lesions
anywhere in the genome, and TC-NER, which is triggered
by lesions in actively transcribed genes that block progres-
sion of the transcription machinery (43). While most NER
factors are involved in both pathways, XPC-RAD23B,
responsible for damage recognition in GG-NER, and
CSA and CSB, involved in early stages of TC-NER,
have pathway-speciﬁc functions (44). We investigated the
requirement for these GG-NER- and TC-NER-speciﬁc
factors in our ICL repair assay. In XPC-deﬁcient cells,
cisplatin ICLs were removed at levels similar as the
XPC-corrected cells, suggesting that the XPC protein
does not play an important role in this repair pathway
(Figure 3A). In contrast, CS-B cells displayed signiﬁcantly
reduced efﬁciency of cisplatin ICL removal, but this defect
was corrected in an isogenic cell line complemented with
the full-length CSB. These results suggest that the repair
of cisplatin ICL proceeds through the TC-NER pathway.
Considering the design of the reporter assay, with the
lesion placed as a block to transcription directed from a
strong promoter, the dependence on TC-NER is perhaps
not unexpected. However, the requirement of CSB was
speciﬁc to cisplatin ICLs, as CSB- and XPC-deﬁcient
cells did not display reduced repair activity of the
1,3-GTG cisplatin intrastrand crosslink (Figure 3B), sug-
gesting that the GG-NER and TC-NER pathways are re-
dundant for this lesion. Therefore, the repair of cisplatin
inter-, but not intrastrand crosslinks is speciﬁcally depend-
ent on TC-NER in our assay conditions.
Reactivation of transcription of cisplatin ICL plasmids is
independent of proteins involved in homologous
recombination, the FA pathway or MMR
Factors involved in homologous recombination (such as
BRCA1/2 or the RAD51 paralogs XRCC2/3,
RAD51B-D) and the FA pathway play a major role in
the metabolism of damage induced by crosslinking
agents (7,45). These factors have been clearly implicated
in replication-dependent ICL repair, but we wished to test
whether they contributed to the removal of ICLs in our
system. We measured levels of ICL repair in the XRCC2-
(irs1) and XRCC3- (irs1SF) mutant hamster cells and
found that the repair of cisplatin ICLs in these RAD51
paralog mutants was comparable with their corresponding
parental cell lines V79B and AA8, respectively
(Supplementary Figure S2A). We also tested the involve-
ment of three FA proteins involved at different stages of
the pathway; FANCA is part of the FA core complex,
FANCD2 protein is monoubiquitinated by the FA core
and regulates incision and translesion synthesis steps in
replication-dependent ICL repair, whereas FANCJ is a
helicase that acts downstream of FANCD2 (7). We
found that the levels of NER-dependent ICL repair of
cisplatin ICLs were the same in FANCA-, FANCD2-
and FANCJ-deﬁcient cells and their complemented coun-
terparts (Supplementary Figure S2B). These studies show
that the repair of the plasmid-based cisplatin ICLs is in-
dependent of homologous recombination and the FA
pathway in this experimental model.
The role of MMR proteins in the recognition and pro-
cessing of ICLs has been controversial. Some studies have
reported that MMR proteins are involved in the process-
ing of ICLs (46–48), in some cases in conjunction with
NER proteins (49), whereas other studies have suggested
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Figure 2. Reactivation of reporter gene expression blocked by a
site-speciﬁc cisplatin ICL depends on NER. Plasmids containing
site-speciﬁc cisplatin lesions: ICL (A) and 1,3-GTG- (B) or 1,2-GG-
(C) intrastrand crosslink were transfected into normal human ﬁbro-
blasts (WT, wild type) and ﬁbroblasts from xeroderma pigmentosum
patients groups A, F and G. XPA(+) are XP-A ﬁbroblasts comple-
mented with wild-type XPA. The relative repair is estimated as percent-
age of the reporter gene activity compared with the undamaged
plasmid, after normalization to an internal cotransfected control.
Standard deviations are shown as error bars.
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that MMR has only a minor effect on ICL repair (50).
Therefore, we tested whether the lack of MMR proteins
inﬂuenced the repair of cisplatin ICLs in our assay.
However, neither the lack of MSH2 in MEFs nor the
lack of MLH1 in an isogenic human cell system (293T
La+ and 293T La) (31,50) had any signiﬁcant inﬂuence
on the repair of cisplatin ICL repair in our system
(Supplementary Figure S2C).
Polymerase f and Rev1 are required for the repair of
cisplatin ICLs
Translesion synthesis (TLS) has been shown to be
involved in the replication-dependent and -independent
repair of ICLs (51). In particular, deﬁciencies in
Polymerase z (composed of Rev3 and Rev7) and Rev1
confer sensitivity to crosslinking agents in avian and mam-
malian cells, and a role for these two factors in ICL repair
has been shown in cellular studies (52–54). In addition to a
role in replication-dependent ICL repair (8), Rev3 and
Rev1 have been speciﬁcally implicated in the repair of
ICLs in the G1 phase of the cell cycle (14,15).
We investigated the repair of our plasmid-based cis-
platin ICLs in Rev3/ and Rev1/ MEFs, and found
the repair efﬁciency to be 4-fold lower than that of the
wild-type cells (Figure 4A). The lack of Rev3 and Rev1
had no impact on the repair of cisplatin-1,3-GTG
intrastrand adducts, as the Rev3/ and Rev1/ cells
were as proﬁcient as the wild-type MEFs (Figure 4B).
The functions of Polz and Rev1 are thus speciﬁcally
required in the recombination-independent pathway of
ICL repair, but not in a classical NER reaction of a
lesion that affects only one DNA strand.
Polg, Pol and Poli are not essential for the repair of
plasmid-based cisplatin ICLs
TLS may require one polymerase or the sequential action
of two different polymerases, one for nucleotide insertion
opposite the damaged base, and the other for the exten-
sion from these termini (55). Furthermore, a number of
TLS polymerases have the ability to bypass ICLs under
certain conditions (56–58). We therefore aimed to deter-
mine whether Y family TLS polymerases are involved in
the replication-independent pathway of cisplatin ICL
repair. PolZ was included, as it is able to bypass certain
ICLs in vitro (56) and PolZ-deﬁcient XP-V cells show
some sensitivity to cisplatin (34,59). Using isogenic pairs
of XP-V and complemented ﬁbroblasts, we found no dif-
ference in the relative repair of cisplatin ICLs (Figure 4C
and Supplementary Figure S3).
Pol is another Y family DNA polymerase with broad
substrate speciﬁcity that has been shown to bypass ICLs
under certain conditions in vitro (55,56). In our reporter
assay, no difference between Pol-deﬁcient and -proﬁcient
MEFs was observed (Figure 4C), suggesting that Pol does
not contribute to the TLS step in our system.
Polk is believed to have a special role in the bypass of
minor-groove lesions, including ICLs, and has addition-
ally been shown to bypass major groove ICLs in vitro
(56,57). Pol/ MEFs showed a small, but reproducible
and statistically signiﬁcant, reduction in the relative repair
of cisplatin ICL compared with the parental Polk-
proﬁcient MEFs (Figure 4C). It is therefore possible that
Polk plays a minor role in this repair pathway, which may
be partially redundant with Polz. This activity may be
related to the recently described activity of Polk in NER
(60). However, the contribution of Polk to repair was
speciﬁc to cisplatin ICL, as the repair of 1,3-GTG
intrastrand crosslink was not affected in its absence
(Figure 4D).
The replication-independent cisplatin ICL
repair is error-free
ICLs are potentially mutagenic lesions and it has been
directly shown that repair of psoralen- and MMC-
induced ICLs can be mutagenic (16,17,61). We therefore
investigated the ﬁdelity of the repair of cisplatin ICLs in
our plasmid-based assay. The crosslinked bases (GpC) are
located within a BsrBI recognition site that is inactivated
by the cisplatin lesion or by mutagenic repair. Cisplatin
ICL containing plasmids were transfected into various
mammalian cell lines, recovered after 20 h and analysed
after transformation into a NER- and recombination-
deﬁcient bacterial strain (AB2480) (38). Since the repli-
cation efﬁciency of cisplatin ICL-containing plasmid
transformed directly to AB2480 was only 1.7%
compared with the undamaged control plasmid, the
clones obtained with the DNA extracted from mammalian
ICL
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Figure 3. The repair of cisplatin ICLs depends on TC-NER, but not
GG-NER. ICL- (A) or 1,3-GTG-intrastrand crosslink– (B) containing
plasmids were transfected into XP-C (XPC), XP-C corrected with WT-
XPC [XPC(+)], CS-B (CSB) and CS-B corrected with WT-CSB
[CSB(+)] ﬁbroblast cell lines and the relative repair activity measured
as in Figure 2.
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cells represent almost exclusively repair events that have
occurred in the transfected cells. The repair of cisplatin
ICLs was highly accurate, as BsrBI was able to digest
the DNA of 124 clones recovered from wild-type human
ﬁbroblasts (Table 1). This observation suggests that the
TLS step in the bypass of ICLs, likely mediated by Rev1
and Polz, is accurate. Interestingly, we also failed to detect
any mutations in the cells with defects in NER, repre-
sented by XP-A cells, and in Rev1 and Rev3 mutant
cells, suggesting that the pathway operating in the
absence of NER and TLS is also accurate. The same
high ﬁdelity of repair was observed in cells with
deﬁciencies in PolZ or Pol. Only in Pol/ MEFs did
we ﬁnd a very low percentage of point mutations (1.1%)
within the BsrBI site, but a similar frequency of mutations
(1.0%) occurred in the Polk proﬁcient MEFs, so we
cannot make a deﬁnite statement that this is due to a de-
ﬁciency of this enzyme. As previous published studies
using similar reporter systems (13,16,17) and the same
bacterial strain as well as our own studies with a
nitrogen-mustard like lesion (62) (Enoiu M, Angelov T,
Scha¨rer OD, unpublished observations) yielded signiﬁcant
mutation rates, we are conﬁdent that the lack of mutations
at cisplatin ICLs reﬂects error-free repair.
Cells with defects in TC-NER are sensitive to interstrand
crosslinking agents
The NER pathway is believed to play a minor role in ICL
repair, since defects in NER genes (other than ERCC1-
XPF) result in only moderate sensitivity to ICL-forming
agents (63,64). In light of our cisplatin ICL reporter assay
results, we wanted to investigate whether the TC-NER-
dependent pathway contributes to the survival of cells
treated with cisplatin in clonogenic assays. We tested
three isogenic pairs of human ﬁbroblasts (XP-A, XP-C,
CS-B and the corrected counterparts) after treatment
with cisplatin. The XP-A and CS-B cells showed a signiﬁ-
cant 3–4-fold increased sensitivity to cisplatin compared
with the respective corrected cells (18% versus 70%
survival for XPA deﬁcient and complemented cell lines,
and 11% versus 56% for CSB-deﬁcient and comple-
mented cell lines at 0.2 mg/ml cisplatin, respectively,
Figure 5A and C), in agreement with the defect in the
reactivation of transcription in the reporter plasmid
(Figures 2A and 3A) and with previous studies (65,66).
In contrast, XP-C ﬁbroblasts were not hypersensitive to
cisplatin (Figure 5B), again in agreement with the results
from the reporter assay (Figure 3A). Indeed, XP-C cells
were even slightly more resistant to cisplatin than the cor-
rected clone.
To establish the generality of this observation and to
rule out that the observed sensitivity was not due to
toxicity of cisplatin DNA intrastrand crosslinks, we
tested the sensitivity of the same cell lines to MMC.
XPA- and CSB-deﬁcient cells were sensitive to MMC
(Supplementary Figure S4A and C), albeit to a lesser
extent than to cisplatin, while XPC-deﬁcient cells were
slightly resistant (Supplementary Figure S4B). Since the
sensitivity of CS-B cells to MMC was rather small in
cycling cells, we wanted to address the impact of CSB
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Figure 4. The repair of cisplatin ICLs is defective in Rev1/ and Rev3/ cells, to a minor degree in Pol/ cells, but not in XP-V and Pol/
cells. ICL- (A) or 1,3 GTG-intrastrand crosslink– (B) containing plasmids were transfected into WT, Rev3/ and Rev1/ mouse ES cells and the
reactivation of luciferase gene expression measured. The same plasmids were transfected into Pol-deﬁcient (XPV) and -complemented human XP-V
[XPV(+)] cells and Pol- and Pol-positive and deﬁcient mouse ES cells, and levels of reporter gene expression determined (C, D).
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deﬁciency on ICL removal in the absence of replication.
Cells were synchronized in G0/G1 by contact inhibition
and serum starvation, treated with a low dose of MMC
and allowed to repair the damage in G0/G1 before being
released into S-phase. We chose these experimental
settings to mimic a G1 checkpoint arrest, which is defect-
ive in the SV40-transformed ﬁbroblasts because of p53
inactivation (67). At 24 h after release, both CSB-deﬁcient
and -corrected cells showed a similar G2/M arrest
(Figure 6). At 48 h after release, the corrected CS-B cells
overcame the arrest (41.2% versus 34.9% G2/M arrested
cells at 24 h and 48 h, respectively). By contrast,
CSB-deﬁcient cells continued to accumulate in G2/M
(43.6% versus 60.2% G2/M arrested cells at 24 h and
48 h, respectively). The difference in the recovery from
the G2/M arrest after MMC treatment and repair in
G0/G1 suggests that CS-B cells are entering S-phase
with a higher number of unrepaired ICLs, allowing us to
unmask the contribution of the G0/G1 pathway to overall
ICL repair. Indeed, the difference between CSB-deﬁcient
and -corrected cells was masked by the replication-
dependent pathway in cycling cells (data not shown).
Taken together, our data suggest that TC-NER, but not
GG-NER, is an important determinant of sensitivity to
cisplatin and other ICL-forming agents in human ﬁbro-
blasts. The correlation with our reporter assay data
suggests that the sensitivity of TCR mutants is because
of the defect in the removal of ICLs, rather than of the
other adducts formed by cisplatin.
Cells with defective TC-NER are further sensitized to
ICL-forming agents by inhibition of
replication-dependent repair
Our studies strongly suggest that a TC-NER-dependent
pathway contributes to the removal of cisplatin and
MMC ICLs. We therefore asked the question whether
downregulation of replication-dependent ICL repair and
TC-NER-dependent ICL repair would lead to a synergistic
sensitivity to crosslinking agents. FANCD2, a key player
in replication-dependent ICL repair, was downregulated
by siRNA in CSB-deﬁcient and corrected cells
(Figure 5E), and the cells were then exposed to cisplatin
or MMC. We observed a strong increase in the sensitivity
to cisplatin in the CSB-corrected cells on downregulation
of FANCD2 (Figure 5D). The intrinsically high cisplatin
sensitivity of the CSB-deﬁcient cells was further enhanced
after downregulation of FANCD2. Importantly, similar
results were obtained when MMC was used as an ICL
agent instead of cisplatin (Supplementary Figure S4D).
We conclude that replication-dependent and TC-NER–de-
pendent ICL repair act in parallel and are additive in
mediating cell survival following treatment with
crosslinking agents.
DISCUSSION
In this study, we describe a pathway for the repair of
cisplatin-induced ICLs that relies on TC-NER and TLS.
We further show that this pathway appears to be the main
pathway in the G0/G1 phase of the cell cycle, and that it
occurs independently of proteins involved in homologous
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Figure 5. TC-NER–deﬁcient, but not GG-NER deﬁcient cells are sen-
sitive to cisplatin, and the sensitivity is additive to FA pathway. XP-A
(XPA) (A), XP-C (XPC) (B) and CS-B (CSB) (C) ﬁbroblasts and the
corresponding corrected cell lines [XPA(+), XPC(+), CSB(+)] were
treated with the indicated doses of cisplatin and the surviving
fraction determined using clonogenic assays. (D) CSB-deﬁcient and -
complemented cells were transfected with FANCD2-speciﬁc (siD2) and
control (siLuc) siRNAs, treated with cisplatin and the surviving
fraction determined using clonogenic assays. The data in A–D are
plotted as the percentage of colonies that grew on the treated plates
relative to untreated plates±S.E. (error bars). (E) Western blot
showing downregulation of FANCD2 in CS-B and corrected
ﬁbroblasts.
Table 1. Analysis of ﬁdelity of cisplatin ICL repair
Cell line, genotype Clones
analyzed
Mutations
identiﬁed
Human, wild type 124 0
Human, XP-A 99 0
MEFs, wild type 120 0
MEFs, Rev3/ 96 0
MEFs, Rev1/ 120 0
Human, XP-V+Pol 100 0
Human, XP-V 120 0
MEFs, Pol+/+ 197 2
MEFs, Pol/ 258 3
MEFs, Pol+/+ 103 0
MEFs, Pol/ 125 0
DNA extracted from transfected cells was transformed to AB2480
Escherichia coli strain, and individual clones were analyzed by BsrBI
digest. The restoration of BsrBI site is indicative of accurate repair at
the ICL site.
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recombination or the FA pathway implicated in
replication-dependent ICL repair. Importantly, this
pathway contributes to the repair of ICLs with S-phase
speciﬁc pathways, providing important evidence for a role
of ICL repair in G0/G1 to reduce the burden of ICLs
formed by antitumor agents.
TC-NER, but not GG-NER, is involved in the repair
of cisplatin ICLs
Previous studies, including those using plasmid-based
reporter assays similar to ours, have shown that NER is
involved in the replication-independent repair of ICLs
(13,16,17,68). While these studies implicated mainly
GG-NER in the repair of psoralen- and MMC-induced
ICLs, and a combination of TC-NER and GG-NER in
the repair of alkyl ICLs, our studies show that only
TC-NER is involved in the repair of cisplatin ICLs. We
are conﬁdent that this difference is real, as the repair of
cisplatin 1,3-intrastrand crosslinks was achieved by either
TC-NER or GG-NER in our system as anticipated. A role
for TC-NER, but not GG-NER, in the repair of cisplatin
ICLs is also consistent with studies that monitored differ-
ent end points. It has been shown that defects in genes
involved in TC-NER (CSA, CSB), but not in GG-NER
(XPC) were associated with cellular hypersensitivity to
cisplatin exposure (65,66). Furthermore, in vitro studies
have shown that cisplatin ICLs are not incised in an
XPC-dependent manner by GG-NER proteins and that
they do not induce ‘‘futile cycles’’ of incision and repair
synthesis adjacent to the crosslink as has been observed
for psoralen and minor groove alkyl ICLs (69,70). These
studies suggest that XPC-RAD23B, the initial damage-
recognition protein in NER, is unable to bind cisplatin
ICLs, indicating that the unusual structure of this
adduct, in which two C residues opposite the crosslinked
G residues are evicted from the helical stack, are incom-
patible with the geometry of XPC-RAD23B binding to
DNA lesions (71–73).
ICLs are repaired through replication-dependent and -
independent pathways
Currently, it is believed that ICLs are mainly repaired in
the S-phase of the cell cycle in a pathway that depends on
replication and recombination (7,8,45,74). This notion is
based on the observation that cells with defects in
genes that contribute to the S-phase-dependent repair of
ICLs display marked sensitivity to crosslinking agents
(45,54). However, there are an increasing number of
reports describing replication-independent ICL repair
(14–17,68,75–77). Our studies show that inactivation of
genes involved in replication-dependent and -independent
ICL repair have an additive effect on cellular sensitivity
to cisplatin and MMC (Figure 5 and Supplementary
Figure S4), suggesting that repair in both the S/G2 and
G0/G1 phases of the cell cycle contribute to cellular
survival following treatment with ICL-forming agents.
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To the best of our knowledge, this has not been previously
demonstrated. It is likely that the importance of
replication-independent ICL repair has been overlooked
because the acute toxicity caused by ICLs is much more
pronounced during S-phase. Here, even a single ICL con-
stitutes an absolute block to replication, therefore prevent-
ing completion of genome duplication and S-phase in the
absence of repair. By contrast, ICLs are more readily
tolerated in the absence of replication, where most of
the genome is not actively utilized. Our data showing
that CSB-deﬁcient cells emerge from G1 with a higher
damage load following treatment with MMC than CSB-
proﬁcient cells (Figure 6) clearly demonstrates the import-
ance of TC-NER in repairing ICLs outside of S-phase. We
note that genes with involvement in replication-dependent
and -independent ICL repair, such as ERCC1-XPF or
REV3, are especially sensitive to crosslinking agents
(54). While the relative contributions of G0/G1- and
S/G2-dependent removal of ICLs remain to be
determined, our studies clearly demonstrate the import-
ance of TC-NER, TLS-dependent ICL repair pathway.
What is the contribution of DNA intrastrand crosslinks
versus ICLs to cisplatin toxicity?
Studies of cisplatin toxicity caused by DNA adducts have
focussed mainly on intrastrand crosslinks, as they are
formed 20-fold more frequently that ICLs (78). The
current thinking is that the 1,2-intrastrand crosslinks are
the clinically most relevant adducts, as (i) they are formed
with the highest frequency, (ii) their cellular adduct levels
correlate with clinical efﬁcacy, (iii) transplatin, which is
clinically inactive, cannot form this adduct and (iv) their
repair has been reported to be inhibited by binding of
HMG proteins, which recognize the characteristic bend
of this adduct, shielding them from repair (78,79). These
reports suggest that cisplatin appears to differ from other
crosslinking agents such as nitrogen mustards, MMC or
chloroethyl nitrosoureas, for which it has been clearly
shown that the ICLs are therapeutically most important
adducts (reviewed in (1,2)).
Based on our and other recent studies, we believe that
the importance of cisplatin ICL in mediating cellular
toxicity should be reevaluated. Because of lower frequency
of formation and increased difﬁculty of synthesis of
deﬁned adducts for functional studies, the biological re-
sponses of ICLs are less well studied than those of the
intrastrand crosslinks. However, in functional studies, cis-
platin behaves similarly to other crosslinking agents such
as MMC or nitrogen mustards, and their ICL adducts are
processed in similar ways (10). Furthermore, recent
studies have shown a correlation of cisplatin ICL repair
levels with the sensitivity of tumor cell lines (80). Our data,
along with studies of cellular sensitivities (65,66), suggest
that outside of replication, cisplatin ICLs can only be
repaired by TC-NER, but not GG-NER. This property
would lead to higher relative levels of ICLs versus
intrastrand crosslink adducts, leading to a strong cyto-
toxic response to the cisplatin ICLs when the cells enter
S-phase. We therefore suggest that the relative importance
of cisplatin inter- versus intrastrand crosslinks deserves
new consideration.
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